AI Article Synopsis
Article Abstract
Background: Intra-aortic balloon pump (IABP) and Impella device utilization as a bridge to heart transplantation (HTx) have risen exponentially. We aimed to explore the influence of device selection on HTx outcomes, considering regional practice variation.
Methods: A retrospective longitudinal study was performed on a United Network for Organ Sharing (UNOS) registry dataset. We included adult patients listed for HTx between October 2018 and April 2022 as status 2, as justified by requiring IABP or Impella support. The primary end-point was successful bridging to HTx as status 2.
Results: Of 32,806 HTx during the study period, 4178 met inclusion criteria (Impella n = 650, IABP n = 3528). Waitlist mortality increased from a nadir of 16 (in 2019) to a peak of 36 (in 2022) per thousand status 2 listed patients. Impella annual use increased from 8% in 2019 to 19% in 2021. Compared to IABP, Impella patients demonstrated higher medical acuity and lower success rate of transplantation as status 2 (92.1% vs 88.9%, p < 0.001). The IABP:Impella utilization ratio varied widely between regions, ranging from 1.77 to 21.31, with high Impella use in Southern and Western states. However, this difference was not justified by medical acuity, regional transplant volume, or waitlist time and did not correlate with waitlist mortality.
Conclusions: The shift in utilizing Impella as opposed to IABP did not improve waitlist outcomes. Our results suggest that clinical practice patterns beyond mere device selection determine successful bridging to HTx. There is a critical need for objective evidence to guide tMCS utilization and a paradigm shift in the UNOS allocation system to achieve equitable HTx practice across the United States.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healun.2023.06.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Mechanical Circulatory Support in Acute Myocardial Infraction Related Cardiogenic Shock.
Catheter Cardiovasc Interv
December 2024
Department of Cardiology, University Hospital Waterford, Waterford, Ireland.
Background: Acute myocardial infarction-related cardiogenic shock (AMICS) is a severe complication associated with exceedingly high mortality rates. While mechanical circulatory support (MCS) has emerged as a potential intervention, the evidence base for independent MCS use remains weak. In contrast, systematic reviews of observational studies have revealed significant mortality reduction when a combination of MCS was used: VA-ECMO in conjunction with a left ventricular (LV) unloading device (Impella or IABP).
View Article and Find Full Text PDFImpact of ECPELLA support on 1-year outcomes and myocardial damage in patients with acute myocardial infarction and refractory cardiogenic shock: A single-center retrospective observational study.
J Cardiol
December 2024
Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Background: Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) is a vital mechanical circulatory support for treating patients with refractory cardiogenic shock (CS). VA-ECMO can improve end-organ perfusion; however, it increases left ventricular (LV) afterload, resulting in further myocardial damage. ECPELLA, a combination of VA-ECMO and Impella (Abiomed Inc.
View Article and Find Full Text PDF[How to Insert an Intraaortic Balloon Pumping( IABP)].
Kyobu Geka
September 2024
Department of Cardiovascular Surgery, Kyorin University, Mitaka, Japan.
Article Synopsis
- * Cardiovascular surgeons need to be skilled in the use and management of IABP, even though it's typically inserted by interventional cardiologists using radiofluoroscopic guidance.
- * The paper outlines a safe approach for performing IABP insertion using transesophageal echocardiography (TEE) guidance, particularly in challenging situations during cardiac surgeries.
Efficacy and safety of percutaneous mechanical circulatory support in patients with cardiogenic shock following acute myocardial infarction: A meta-analysis of randomized controlled trials.
Medicine (Baltimore)
November 2024
Department of Surgery, University of New Mexico Health Sciences, Albuquerque, NM.
Article Synopsis
- Cardiogenic shock (CS) is a serious complication of acute myocardial infarction (AMI) and can lead to high mortality rates; this study evaluates the effectiveness of the Impella device in treating CS.* -
- A meta-analysis of four random controlled trials with a total of 442 patients showed that Impella use resulted in significantly lower 6-month all-cause mortality compared to standard care, though 30-day mortality was not significantly different.* -
- However, patients using Impella experienced significantly higher odds of major bleeding, limb ischemia, and sepsis, indicating potential risks associated with its use.*
Impella 5.5 as a bridge-to-surgery in acute ischemic mitral regurgitation post-percutaneous coronary intervention: a case report.
J Cardiothorac Surg
November 2024
Division of Advanced Heart Failure and Cardiac Transplant, University of South Florida, Tampa General Hospital, 7110 S Trask Street, Tampa, FL, 33616, USA.
Article Synopsis
- Acute ischemic mitral regurgitation (AIMR) is a serious condition that can occur during acute coronary syndrome, leading to rapid heart failure and shock; intra-aortic balloon pumps (IABP) are often used to stabilize patients before surgery.
- A 74-year-old man with cardiac issues underwent an initial stenting procedure but continued to experience severe hypoxia and hypotension, prompting the upgrade to an Impella device for better circulatory support.
- Although his condition improved enough for surgery to replace the mitral valve and perform bypass grafting, he later developed bacterial pneumonia and acute respiratory distress syndrome, leading to his death shortly after.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!